UM-164: a potent c-Src/p38 kinase inhibitor with in vivo activity against triple negative breast cancer.
about
The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design.Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia.Emergence of a Promising Lead Compound in the Treatment of Triple Negative Breast Cancer: An Insight into Conformational Features and Ligand Binding Landscape of c-Src Protein with UM-164.Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
P2860
UM-164: a potent c-Src/p38 kinase inhibitor with in vivo activity against triple negative breast cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
UM-164: a potent c-Src/p38 kin ...... triple negative breast cancer.
@en
type
label
UM-164: a potent c-Src/p38 kin ...... triple negative breast cancer.
@en
prefLabel
UM-164: a potent c-Src/p38 kin ...... triple negative breast cancer.
@en
P2093
P1476
UM-164: a potent c-Src/p38 kin ...... triple negative breast cancer.
@en
P2093
Carrie R Graveel
Eric Lachacz
Frank Kwarcinski
Kristoffer Brandvold
Li Wei Bao
Matthew B Soellner
Michael Steffey
Michelle Dziubinski
Rabia Gilani
Sameer Phadke
P356
10.1158/1078-0432.CCR-15-2158
P407
P577
2016-05-06T00:00:00Z